Which has better earnings & valuation, ALZN or CNTX?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$8.77M -$2.30 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is ALZN or CNTX more profitable?

Context Therapeutics' return on equity of -82.06% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.88% -184.20% Context Therapeutics N/A -82.06% -72.74%

Does the media refer more to ALZN or CNTX?

In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 0.00 equaled Context Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALZN or MDXH more profitable?

Alzamend Neuro has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.88% -184.20% MDxHealth -33.46% N/A -24.25%

Does the media prefer ALZN or MDXH?

In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GOSS or ALZN?

In the previous week, Gossamer Bio had 3 more articles in the media than Alzamend Neuro. MarketBeat recorded 4 mentions for Gossamer Bio and 1 mentions for Alzamend Neuro. Gossamer Bio's average media sentiment score of 0.14 beat Alzamend Neuro's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALZN or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Alzamend Neuro's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.88% -184.20% Kyntra Bio 2,199.13% N/A -47.27%

Does the media favor ALZN or KYNB?

In the previous week, Kyntra Bio had 2 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Kyntra Bio and 1 mentions for Alzamend Neuro. Kyntra Bio's average media sentiment score of 0.67 beat Alzamend Neuro's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALZN or ALGS?

In the previous week, Aligos Therapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for Aligos Therapeutics and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alzamend Neuro (ALZN) Competitors

$1.89 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.83 -0.06 (-3.39%)

As of 09/18/2026 07:30 PM Eastern

Compare

ALZN vs. CNTX, MDXH, GOSS, KYNB, and ALGS

Should you buy Alzamend Neuro stock or one of its competitors? Alzamend Neuro's main competitors and comparable companies include Context Therapeutics (CNTX), MDxHealth (MDXH), Gossamer Bio (GOSS), Kyntra Bio (KYNB), and Aligos Therapeutics (ALGS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alzamend Neuro compare to Context Therapeutics?

Alzamend Neuro (NASDAQ:ALZN) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Context Therapeutics' return on equity of -82.06% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
Context Therapeutics	N/A	-82.06%	-72.74%

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 1,381.48%. Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,575.27%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Alzamend Neuro has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 0.00 equaled Context Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alzamend Neuro is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Summary

Context Therapeutics beats Alzamend Neuro on 9 of the 11 factors compared between the two stocks.

How does Alzamend Neuro compare to MDxHealth?

Alzamend Neuro (NASDAQ:ALZN) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 1,381.48%. MDxHealth has a consensus price target of $2.17, suggesting a potential upside of 243.92%. Given Alzamend Neuro's higher possible upside, research analysts clearly believe Alzamend Neuro is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alzamend Neuro has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
MDxHealth	$107.88M	0.29	-$33.52M	-$0.72	N/A

49.6% of Alzamend Neuro shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alzamend Neuro has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
MDxHealth	-33.46%	N/A	-24.25%

Alzamend Neuro has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MDxHealth beats Alzamend Neuro on 8 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Gossamer Bio currently has a consensus price target of $256.00, suggesting a potential upside of 2,285.83%. Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 1,381.48%. Given Gossamer Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Gossamer Bio is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alzamend Neuro has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Alzamend Neuro	N/A	-277.88%	-184.20%

Alzamend Neuro has lower revenue, but higher earnings than Gossamer Bio. Alzamend Neuro is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.65	-$170.37M	-$56.00	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A

Gossamer Bio has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

In the previous week, Gossamer Bio had 3 more articles in the media than Alzamend Neuro. MarketBeat recorded 4 mentions for Gossamer Bio and 1 mentions for Alzamend Neuro. Gossamer Bio's average media sentiment score of 0.14 beat Alzamend Neuro's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Gossamer Bio beats Alzamend Neuro on 12 of the 15 factors compared between the two stocks.

How does Alzamend Neuro compare to Kyntra Bio?

Alzamend Neuro (NASDAQ:ALZN) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Kyntra Bio has higher revenue and earnings than Alzamend Neuro. Alzamend Neuro is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
Kyntra Bio	$6.44M	4.45	$183.45M	$45.30	0.16

Alzamend Neuro has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kyntra Bio has a net margin of 2,199.13% compared to Alzamend Neuro's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
Kyntra Bio	2,199.13%	N/A	-47.27%

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 1,381.48%. Kyntra Bio has a consensus price target of $37.25, suggesting a potential upside of 426.87%. Given Alzamend Neuro's higher probable upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Kyntra Bio had 2 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Kyntra Bio and 1 mentions for Alzamend Neuro. Kyntra Bio's average media sentiment score of 0.67 beat Alzamend Neuro's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kyntra Bio beats Alzamend Neuro on 15 of the 16 factors compared between the two stocks.

How does Alzamend Neuro compare to Aligos Therapeutics?

Alzamend Neuro (NASDAQ:ALZN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Alzamend Neuro has higher earnings, but lower revenue than Aligos Therapeutics. Alzamend Neuro is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
Aligos Therapeutics	$31.52M	1.04	-$24.19M	-$7.30	N/A

Alzamend Neuro currently has a consensus price target of $28.00, indicating a potential upside of 1,381.48%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 634.73%. Given Alzamend Neuro's higher possible upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Alzamend Neuro has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

In the previous week, Aligos Therapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for Aligos Therapeutics and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alzamend Neuro has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market.

Summary

Aligos Therapeutics beats Alzamend Neuro on 11 of the 15 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.13M	$3.89B	$7.22B	$12.94B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-0.82	14.23	275.51	25.40
Price / Sales	N/A	1,357.37	630.02	78.28
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	9.95	15.47	10.50	6.32
Net Income	-$8.77M	-$22.90M	$3.49B	$358.20M
7 Day Performance	8.00%	-1.36%	-0.25%	0.42%
1 Month Performance	21.15%	-4.54%	-2.69%	-3.30%
1 Year Performance	-21.25%	37.74%	18.14%	5.33%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	2.5219 of 5 stars	$1.89 flat	$28.00 +1,381.5%	-21.3%	$9.13M	N/A	N/A	6	High Trading Volume
CNTX Context Therapeutics	2.3741 of 5 stars	$0.37 +2.6%	$6.17 +1,548.8%	-62.0%	$34.36M	N/A	N/A	7	Gap Up
MDXH MDxHealth	2.0998 of 5 stars	$0.68 +0.9%	$2.17 +219.1%	-84.8%	$33.61M	$107.88M	N/A	300	Positive News
GOSS Gossamer Bio	2.4641 of 5 stars	$10.73 +3.3%	$256.00 +2,286.5%	-95.6%	$31.43M	$48.47M	N/A	180	News Coverage Analyst Downgrade Gap Up
KYNB Kyntra Bio	3.8688 of 5 stars	$7.75 -0.3%	$36.00 +364.5%	N/A	$31.39M	$6.44M	0.17	570	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. CNTX, MDXH, GOSS, KYNB, and ALGS

How does Alzamend Neuro compare to Context Therapeutics?

Summary

How does Alzamend Neuro compare to MDxHealth?

Summary

How does Alzamend Neuro compare to Gossamer Bio?

Summary

How does Alzamend Neuro compare to Kyntra Bio?

Summary

How does Alzamend Neuro compare to Aligos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. CNTX, MDXH, GOSS, KYNB, and ALGS

How does Alzamend Neuro compare to Context Therapeutics?

Do insiders & institutionals believe in ALZN or CNTX?

Is ALZN or CNTX more profitable?

Do analysts prefer ALZN or CNTX?

Which has more risk & volatility, ALZN or CNTX?

Does the media refer more to ALZN or CNTX?

Which has better earnings & valuation, ALZN or CNTX?

Summary

How does Alzamend Neuro compare to MDxHealth?

Do analysts rate ALZN or MDXH?

Which has stronger earnings and valuation, ALZN or MDXH?

Do insiders & institutionals hold more shares of ALZN or MDXH?

Is ALZN or MDXH more profitable?

Which has more volatility and risk, ALZN or MDXH?

Does the media prefer ALZN or MDXH?

Summary

How does Alzamend Neuro compare to Gossamer Bio?

Do analysts prefer GOSS or ALZN?

Is GOSS or ALZN more profitable?

Which has better earnings and valuation, GOSS or ALZN?

Which has more risk & volatility, GOSS or ALZN?

Does the media prefer GOSS or ALZN?

Do institutionals & insiders hold more shares of GOSS or ALZN?

Summary

How does Alzamend Neuro compare to Kyntra Bio?

Which has stronger earnings and valuation, ALZN or KYNB?

Which has more volatility & risk, ALZN or KYNB?

Do insiders and institutionals hold more shares of ALZN or KYNB?

Is ALZN or KYNB more profitable?

Do analysts recommend ALZN or KYNB?

Does the media favor ALZN or KYNB?

Summary

How does Alzamend Neuro compare to Aligos Therapeutics?

Which has better earnings & valuation, ALZN or ALGS?

Do analysts rate ALZN or ALGS?

Is ALZN or ALGS more profitable?

Does the media favor ALZN or ALGS?

Do institutionals and insiders have more ownership in ALZN or ALGS?

Which has more volatility & risk, ALZN or ALGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools